Vir Biotechnology, Inc.
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $238.90M | $0.47 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | -$29.00K | $-0.85 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 23, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $200.00K | $-1.17 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $1.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $3.00M | $-0.88 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $12.40M | $-0.76 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | After market close | $2.40M | $-1.56 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | After market close | – | – | – |
Press releases
Announcements Vir Biotechnology filed with the SEC
Vir Biotechnology Enters Multi-Program Collaboration and License
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
ASTELLAS AND VIR BIO JOINT PRESS RELEASE
Material agreement · Results of operations · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Material agreement · Results of operations · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN ® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Material agreement · Results of operations · Unregistered share sale · Other events · EX-99.3 to Form 8-K
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
January 14, 2026 J.P. Morgan 2026 Healthcare Conference 2026 Vir Biotechnology, Inc. 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology announces closing of exclusive worldwide license agreement with Sanofi for multiple potential best-in-class clinical-stage T-Cell engagers
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for
Other events · EX-99.1 to Form 8-K
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT
Regulation FD disclosure · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
Executive or director change · Other events · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Material agreement · Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
Results of operations · Other events · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Results of operations · EX-99 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Results of operations · EX-99 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and
Other events · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Results of operations · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Results of operations · EX-99.1 to Form 8-K
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2
Other events · EX-99.1 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
revenue related to binding agreements for doses of sotrovimab) of Vir Biotechnology, Inc. (the “Company”), the timing and expected number of therapeutic doses of sotrovimab that the Company will be able to supply to patients, the ability
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Vir Biotechnology Provides Corporate Update and Reports
Results of operations · EX-99.1 to Form 8-K